Convalescent Plasma Therapy in the management of COVID-19 patients-The newer dimensions
COVID 19 infection caused by novel coronavirus with no specific established treatment. Convalescent Plasma Therapy has been authorized as an off-label therapeutic procedure. We assessed the outcome of convalescent plasma (CP) units versus standard treatment on the complete recovery, improvement and...
Gespeichert in:
| Veröffentlicht in: | Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine 2021-08, Vol.28 (3), p.246-253 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 253 |
|---|---|
| container_issue | 3 |
| container_start_page | 246 |
| container_title | Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine |
| container_volume | 28 |
| creator | Mahapatra, S. Rattan, R. Mohanty, C.B.K. |
| description | COVID 19 infection caused by novel coronavirus with no specific established treatment. Convalescent Plasma Therapy has been authorized as an off-label therapeutic procedure. We assessed the outcome of convalescent plasma (CP) units versus standard treatment on the complete recovery, improvement and 28 days’ mortality of COVID 19 patients.
The present was multi-centric case controlled observational prospective study. The study was conducted for a period of four and half months from July 15 2020 to 30 November 2020 after taking approval from the Expert Committee, Health & Family Welfare Department, Government of Odisha. Plasma therapy was applied on two groups of 1189 serious COVID patients (959 number of pre- critical and 230 number of critical patients) not responding to oxygen therapy. It was compared with non- transfused control group of 1243 patients (996 number of pre-critical and 247 number of critical patients).
Discharge was better in (55.5%) transfused than (43%)in non-transfused pre-critical patients and the mortality was lower (44.3%) in transfused, (48.9%) than non-transfused critical patients respectively. Complete recovery was highest in those who were transfused with CP with neutralizing titer more than 1:160 (52.5%), 18–30 years’ age group (64%), females (53%), ‘O’ Rh D positive blood group (51.5%). There was no adverse reaction due to CP transfusion.
CP is effective in improving the recovery rate with earlier discharge and decrease in the 28 days’ mortality than in the control non-transfused group. CP with neutralizing antibody titer more than 1:160 has the best outcome with complete recovery and decrease in the mortality. It is more effective in treating pre-critical patients when transfused early, in female patients, in younger age group and in blood group ‘O’ Rh D positive. |
| doi_str_mv | 10.1016/j.tracli.2021.04.009 |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8132190</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1246782021000707</els_id><sourcerecordid>33965621</sourcerecordid><originalsourceid>FETCH-LOGICAL-c463t-c6c232cc49abd64f0778e52c33edefa1b32ef40ecb2828e703a22318a2386c213</originalsourceid><addsrcrecordid>eNp9kMtOwzAQRS0EoqXwBwj5BxLscZrHBgmFV6VKZVFgabnOpHWVl-xQ1L_HVaHAhtVY43vvzBxCLjkLOePx9TrsrdKVCYEBD1kUMpYdkSHPxiJIGcCxf0MUB0kKbEDOnFszxhOeJadkIEQWj2PgQ_KWt81GVeg0Nj19rpSrFZ2v0KpuS01D-xXSWjVqifVO0JY0n71O7gKe0U71xvdc4OW0wQ-0tDBe5UzbuHNyUqrK4cVXHZGXh_t5_hRMZ4-T_HYa6CgWfaBjDQK0jjK1KOKoZEmS4hi0EFhgqfhCAJYRQ72AFFJMmFAAgqcKROqtXIzIzT63e1_UWOyusKqSnTW1slvZKiP__jRmJZftRqZcAM-YD4j2Adq2zlksD17O5A60XMs9aLkDLVkkPWhvu_o992D6JvuzGPrrNwatdNrj0lgYi7qXRWv-n_AJUHySaw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Convalescent Plasma Therapy in the management of COVID-19 patients-The newer dimensions</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Mahapatra, S. ; Rattan, R. ; Mohanty, C.B.K.</creator><creatorcontrib>Mahapatra, S. ; Rattan, R. ; Mohanty, C.B.K.</creatorcontrib><description>COVID 19 infection caused by novel coronavirus with no specific established treatment. Convalescent Plasma Therapy has been authorized as an off-label therapeutic procedure. We assessed the outcome of convalescent plasma (CP) units versus standard treatment on the complete recovery, improvement and 28 days’ mortality of COVID 19 patients.
The present was multi-centric case controlled observational prospective study. The study was conducted for a period of four and half months from July 15 2020 to 30 November 2020 after taking approval from the Expert Committee, Health & Family Welfare Department, Government of Odisha. Plasma therapy was applied on two groups of 1189 serious COVID patients (959 number of pre- critical and 230 number of critical patients) not responding to oxygen therapy. It was compared with non- transfused control group of 1243 patients (996 number of pre-critical and 247 number of critical patients).
Discharge was better in (55.5%) transfused than (43%)in non-transfused pre-critical patients and the mortality was lower (44.3%) in transfused, (48.9%) than non-transfused critical patients respectively. Complete recovery was highest in those who were transfused with CP with neutralizing titer more than 1:160 (52.5%), 18–30 years’ age group (64%), females (53%), ‘O’ Rh D positive blood group (51.5%). There was no adverse reaction due to CP transfusion.
CP is effective in improving the recovery rate with earlier discharge and decrease in the 28 days’ mortality than in the control non-transfused group. CP with neutralizing antibody titer more than 1:160 has the best outcome with complete recovery and decrease in the mortality. It is more effective in treating pre-critical patients when transfused early, in female patients, in younger age group and in blood group ‘O’ Rh D positive.</description><identifier>ISSN: 1246-7820</identifier><identifier>EISSN: 1953-8022</identifier><identifier>DOI: 10.1016/j.tracli.2021.04.009</identifier><identifier>PMID: 33965621</identifier><language>eng</language><publisher>France: Elsevier Masson SAS</publisher><subject>Adolescent ; Adult ; Age Distribution ; Antibodies, Neutralizing - blood ; Antibodies, Viral - blood ; Antibodies, Viral - immunology ; Antibodies, Viral - therapeutic use ; Blood Group Antigens - analysis ; Case-Control Studies ; Convalescent plasma ; COVID 19 infection ; COVID-19 - blood ; COVID-19 - mortality ; COVID-19 - therapy ; COVID-19 Serotherapy ; Disease Management ; Donor Selection ; Early transfusion ; Female ; Humans ; Immunization, Passive - statistics & numerical data ; India - epidemiology ; Length of Stay - statistics & numerical data ; Male ; Middle Aged ; Mortality ; Original ; Procedures and Techniques Utilization ; Prospective Studies ; SARS-CoV-2 - immunology ; Sex Distribution ; Time Factors ; Treatment Outcome ; Young Adult</subject><ispartof>Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine, 2021-08, Vol.28 (3), p.246-253</ispartof><rights>2021 Société française de transfusion sanguine (SFTS)</rights><rights>Copyright © 2021 Société française de transfusion sanguine (SFTS). Published by Elsevier Masson SAS. All rights reserved.</rights><rights>2021 Société française de transfusion sanguine (SFTS). Published by Elsevier Masson SAS. All rights reserved. 2021 Société française de transfusion sanguine (SFTS)</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c463t-c6c232cc49abd64f0778e52c33edefa1b32ef40ecb2828e703a22318a2386c213</citedby><cites>FETCH-LOGICAL-c463t-c6c232cc49abd64f0778e52c33edefa1b32ef40ecb2828e703a22318a2386c213</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S1246782021000707$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,314,776,780,881,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33965621$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Mahapatra, S.</creatorcontrib><creatorcontrib>Rattan, R.</creatorcontrib><creatorcontrib>Mohanty, C.B.K.</creatorcontrib><title>Convalescent Plasma Therapy in the management of COVID-19 patients-The newer dimensions</title><title>Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine</title><addtitle>Transfus Clin Biol</addtitle><description>COVID 19 infection caused by novel coronavirus with no specific established treatment. Convalescent Plasma Therapy has been authorized as an off-label therapeutic procedure. We assessed the outcome of convalescent plasma (CP) units versus standard treatment on the complete recovery, improvement and 28 days’ mortality of COVID 19 patients.
The present was multi-centric case controlled observational prospective study. The study was conducted for a period of four and half months from July 15 2020 to 30 November 2020 after taking approval from the Expert Committee, Health & Family Welfare Department, Government of Odisha. Plasma therapy was applied on two groups of 1189 serious COVID patients (959 number of pre- critical and 230 number of critical patients) not responding to oxygen therapy. It was compared with non- transfused control group of 1243 patients (996 number of pre-critical and 247 number of critical patients).
Discharge was better in (55.5%) transfused than (43%)in non-transfused pre-critical patients and the mortality was lower (44.3%) in transfused, (48.9%) than non-transfused critical patients respectively. Complete recovery was highest in those who were transfused with CP with neutralizing titer more than 1:160 (52.5%), 18–30 years’ age group (64%), females (53%), ‘O’ Rh D positive blood group (51.5%). There was no adverse reaction due to CP transfusion.
CP is effective in improving the recovery rate with earlier discharge and decrease in the 28 days’ mortality than in the control non-transfused group. CP with neutralizing antibody titer more than 1:160 has the best outcome with complete recovery and decrease in the mortality. It is more effective in treating pre-critical patients when transfused early, in female patients, in younger age group and in blood group ‘O’ Rh D positive.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Age Distribution</subject><subject>Antibodies, Neutralizing - blood</subject><subject>Antibodies, Viral - blood</subject><subject>Antibodies, Viral - immunology</subject><subject>Antibodies, Viral - therapeutic use</subject><subject>Blood Group Antigens - analysis</subject><subject>Case-Control Studies</subject><subject>Convalescent plasma</subject><subject>COVID 19 infection</subject><subject>COVID-19 - blood</subject><subject>COVID-19 - mortality</subject><subject>COVID-19 - therapy</subject><subject>COVID-19 Serotherapy</subject><subject>Disease Management</subject><subject>Donor Selection</subject><subject>Early transfusion</subject><subject>Female</subject><subject>Humans</subject><subject>Immunization, Passive - statistics & numerical data</subject><subject>India - epidemiology</subject><subject>Length of Stay - statistics & numerical data</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Mortality</subject><subject>Original</subject><subject>Procedures and Techniques Utilization</subject><subject>Prospective Studies</subject><subject>SARS-CoV-2 - immunology</subject><subject>Sex Distribution</subject><subject>Time Factors</subject><subject>Treatment Outcome</subject><subject>Young Adult</subject><issn>1246-7820</issn><issn>1953-8022</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kMtOwzAQRS0EoqXwBwj5BxLscZrHBgmFV6VKZVFgabnOpHWVl-xQ1L_HVaHAhtVY43vvzBxCLjkLOePx9TrsrdKVCYEBD1kUMpYdkSHPxiJIGcCxf0MUB0kKbEDOnFszxhOeJadkIEQWj2PgQ_KWt81GVeg0Nj19rpSrFZ2v0KpuS01D-xXSWjVqifVO0JY0n71O7gKe0U71xvdc4OW0wQ-0tDBe5UzbuHNyUqrK4cVXHZGXh_t5_hRMZ4-T_HYa6CgWfaBjDQK0jjK1KOKoZEmS4hi0EFhgqfhCAJYRQ72AFFJMmFAAgqcKROqtXIzIzT63e1_UWOyusKqSnTW1slvZKiP__jRmJZftRqZcAM-YD4j2Adq2zlksD17O5A60XMs9aLkDLVkkPWhvu_o992D6JvuzGPrrNwatdNrj0lgYi7qXRWv-n_AJUHySaw</recordid><startdate>20210801</startdate><enddate>20210801</enddate><creator>Mahapatra, S.</creator><creator>Rattan, R.</creator><creator>Mohanty, C.B.K.</creator><general>Elsevier Masson SAS</general><general>Société française de transfusion sanguine (SFTS). Published by Elsevier Masson SAS</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope></search><sort><creationdate>20210801</creationdate><title>Convalescent Plasma Therapy in the management of COVID-19 patients-The newer dimensions</title><author>Mahapatra, S. ; Rattan, R. ; Mohanty, C.B.K.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c463t-c6c232cc49abd64f0778e52c33edefa1b32ef40ecb2828e703a22318a2386c213</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Age Distribution</topic><topic>Antibodies, Neutralizing - blood</topic><topic>Antibodies, Viral - blood</topic><topic>Antibodies, Viral - immunology</topic><topic>Antibodies, Viral - therapeutic use</topic><topic>Blood Group Antigens - analysis</topic><topic>Case-Control Studies</topic><topic>Convalescent plasma</topic><topic>COVID 19 infection</topic><topic>COVID-19 - blood</topic><topic>COVID-19 - mortality</topic><topic>COVID-19 - therapy</topic><topic>COVID-19 Serotherapy</topic><topic>Disease Management</topic><topic>Donor Selection</topic><topic>Early transfusion</topic><topic>Female</topic><topic>Humans</topic><topic>Immunization, Passive - statistics & numerical data</topic><topic>India - epidemiology</topic><topic>Length of Stay - statistics & numerical data</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Mortality</topic><topic>Original</topic><topic>Procedures and Techniques Utilization</topic><topic>Prospective Studies</topic><topic>SARS-CoV-2 - immunology</topic><topic>Sex Distribution</topic><topic>Time Factors</topic><topic>Treatment Outcome</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mahapatra, S.</creatorcontrib><creatorcontrib>Rattan, R.</creatorcontrib><creatorcontrib>Mohanty, C.B.K.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mahapatra, S.</au><au>Rattan, R.</au><au>Mohanty, C.B.K.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Convalescent Plasma Therapy in the management of COVID-19 patients-The newer dimensions</atitle><jtitle>Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine</jtitle><addtitle>Transfus Clin Biol</addtitle><date>2021-08-01</date><risdate>2021</risdate><volume>28</volume><issue>3</issue><spage>246</spage><epage>253</epage><pages>246-253</pages><issn>1246-7820</issn><eissn>1953-8022</eissn><abstract>COVID 19 infection caused by novel coronavirus with no specific established treatment. Convalescent Plasma Therapy has been authorized as an off-label therapeutic procedure. We assessed the outcome of convalescent plasma (CP) units versus standard treatment on the complete recovery, improvement and 28 days’ mortality of COVID 19 patients.
The present was multi-centric case controlled observational prospective study. The study was conducted for a period of four and half months from July 15 2020 to 30 November 2020 after taking approval from the Expert Committee, Health & Family Welfare Department, Government of Odisha. Plasma therapy was applied on two groups of 1189 serious COVID patients (959 number of pre- critical and 230 number of critical patients) not responding to oxygen therapy. It was compared with non- transfused control group of 1243 patients (996 number of pre-critical and 247 number of critical patients).
Discharge was better in (55.5%) transfused than (43%)in non-transfused pre-critical patients and the mortality was lower (44.3%) in transfused, (48.9%) than non-transfused critical patients respectively. Complete recovery was highest in those who were transfused with CP with neutralizing titer more than 1:160 (52.5%), 18–30 years’ age group (64%), females (53%), ‘O’ Rh D positive blood group (51.5%). There was no adverse reaction due to CP transfusion.
CP is effective in improving the recovery rate with earlier discharge and decrease in the 28 days’ mortality than in the control non-transfused group. CP with neutralizing antibody titer more than 1:160 has the best outcome with complete recovery and decrease in the mortality. It is more effective in treating pre-critical patients when transfused early, in female patients, in younger age group and in blood group ‘O’ Rh D positive.</abstract><cop>France</cop><pub>Elsevier Masson SAS</pub><pmid>33965621</pmid><doi>10.1016/j.tracli.2021.04.009</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1246-7820 |
| ispartof | Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine, 2021-08, Vol.28 (3), p.246-253 |
| issn | 1246-7820 1953-8022 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8132190 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Adolescent Adult Age Distribution Antibodies, Neutralizing - blood Antibodies, Viral - blood Antibodies, Viral - immunology Antibodies, Viral - therapeutic use Blood Group Antigens - analysis Case-Control Studies Convalescent plasma COVID 19 infection COVID-19 - blood COVID-19 - mortality COVID-19 - therapy COVID-19 Serotherapy Disease Management Donor Selection Early transfusion Female Humans Immunization, Passive - statistics & numerical data India - epidemiology Length of Stay - statistics & numerical data Male Middle Aged Mortality Original Procedures and Techniques Utilization Prospective Studies SARS-CoV-2 - immunology Sex Distribution Time Factors Treatment Outcome Young Adult |
| title | Convalescent Plasma Therapy in the management of COVID-19 patients-The newer dimensions |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-09T09%3A45%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Convalescent%20Plasma%20Therapy%20in%20the%20management%20of%20COVID-19%20patients-The%20newer%20dimensions&rft.jtitle=Transfusion%20clinique%20et%20biologique%20:%20journal%20de%20la%20Societe%20francaise%20de%20transfusion%20sanguine&rft.au=Mahapatra,%20S.&rft.date=2021-08-01&rft.volume=28&rft.issue=3&rft.spage=246&rft.epage=253&rft.pages=246-253&rft.issn=1246-7820&rft.eissn=1953-8022&rft_id=info:doi/10.1016/j.tracli.2021.04.009&rft_dat=%3Cpubmed_cross%3E33965621%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/33965621&rft_els_id=S1246782021000707&rfr_iscdi=true |